AcelRx Tries Transparency To Reassure Investors After Zalviso ‘Complete Response’
This article was originally published in The Pink Sheet Daily
Executive Summary
Trying to beat The Medicines Co. to market with a patient-administered post-surgical pain analgesic, AcelRx hopes it can re-file the NDA for Zalviso by the end of 2014, based on already filed amendments and adjustments to the delivery mechanism and instructions for use.